Immediate Impact

1 from Science/Nature 58 hit
Sub-graph 1 of 22

Citing Papers

Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy
2025 Hit
Lipid metabolic reprograming: the unsung hero in breast cancer progression and tumor microenvironment
2025 Hit
2 intermediate papers

Works of Vanesa Quiroga being referenced

Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial.
2023
Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor–positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study.
2022
and 1 more

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Vanesa Quiroga 183 154 88 84 73 39 314
Nieves Martínez Chanzá 204 1.1× 105 0.7× 122 1.4× 38 0.5× 58 0.8× 32 324
Hyun Jung Lee 81 0.4× 120 0.8× 61 0.7× 70 0.8× 100 1.4× 46 322
Jeremy Rosenblum 139 0.8× 138 0.9× 29 0.3× 70 0.8× 128 1.8× 29 344
Ashray Gunjur 114 0.6× 83 0.5× 101 1.1× 51 0.6× 79 1.1× 30 330
Takumi Fujimura 85 0.5× 81 0.5× 119 1.4× 60 0.7× 108 1.5× 26 356
Chang Hun Lee 171 0.9× 86 0.6× 62 0.7× 74 0.9× 91 1.2× 29 340
Luca Visani 150 0.8× 175 1.1× 73 0.8× 78 0.9× 31 0.4× 40 337
Theodore Stewart Gourdin 171 0.9× 127 0.8× 85 1.0× 80 1.0× 105 1.4× 39 366
Satoshi Fukata 81 0.4× 123 0.8× 107 1.2× 83 1.0× 154 2.1× 32 344
U Ambus 142 0.8× 57 0.4× 66 0.8× 32 0.4× 61 0.8× 26 343

All Works

Loading papers...

Rankless by CCL
2026